Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 1.01, 9.01 · 8-K

Tessera Defense and Homeland Security Inc.

Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Tessera Defense and Homeland Security Israel Ltd. (“Tessera Israel”), a wholly owned subsidiary of Tessera Defense and Homeland Security Inc. (the “Company”), entered into an Option Agreement (the “Option Agreement”) with X S.E. Security and Defense Ltd. (“X SE”) for the purchase of all of the shares of RT LTA Systems Ltd.…

Filed Sep 25, 2026Accepted Sep 25, 2026, 8:42 AM EDTCIK 1739174Accession 0001213900-26-103251
Share

Company context

BiomX Inc. is a company focused on acquiring and further developing technologies that identify, track, and respond to physical threats across defense, security, critical infrastructure, and first-response sectors. The Company's portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.

Current securities

Historical securities (3)

Recent company filings

  1. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesSep 22, 2026
  2. SCHEDULE 13D filingSep 17, 2026
  3. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureSep 15, 2026
  4. SCHEDULE 13D/A filingSep 15, 2026
  5. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearSep 9, 2026

Registered securities in this filing

TESSERA DEFENSE AND HOMELAND SECURITY INC. · 8-K · Filed 2026-09-25

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value per share

Symbol
HLSQ
Exchange
NYSEAMER
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-09-24

Dimensions: Not supplied

Accession 000121390026103251 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 1.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Tessera Defense and Homeland Security Israel Ltd. (“Tessera Israel”), a wholly owned subsidiary of Tessera Defense and Homeland Security Inc. (the “Company”), entered into an Option Agreement (the “Option Agreement”) with X S.E. Security and Defense Ltd. (“X SE”) for the purchase of all of the shares of RT LTA Systems Ltd. (“RT”), held by X SE, representing 51% of the issued and outstanding share capital of RT on a fully diluted basis (the “RT Shares”). RT is an Israeli company that develops and manufactures tethered aerostat systems for persistent airborne surveillance and communications. Under the Option Agreement, X SE granted Tessera Israel, or any designated affiliate of Tessera Israel, including the Company, the right, but not the obligation, to purchase all, but not less than all, of the RT Shares held by X SE (the “Option”). Tessera Israel may exercise the Option by written notice at any time within 90 days after the date of the Option Agreement. The exercise of the Option is subject to a due diligence review by Tessera Israel, with results satisfactory to Tessera Israel in its sole discretion, and to the receipt of required approvals, including the approval of the boards of directors of the parties and of the Company, any consent or waiver required from the other shareholders of RT, any required approval of the Israeli Ministry of Defense and any required approval of or notice to the Israel Innovation Authority. Notwithstanding the foregoing, Tessera Israel may terminate the Option Agreement at any time by written notice, including prior to the option exercise period. Within 30 days after the date of the Option Agreement, unless the Option Agreement is terminated before then, Tessera Israel undertook to remit to X SE $1,000,000 as consideration for the Option (the “Option Consideration”). The Option Consideration will be credited against the purchase price upon the exercise of the Option (if any). The Option Consideration will be refunded to Tessera Israel if the Option is not exercised or the Option Agreement terminates, including if the Option is not exercised within the exercise period. Any other amount paid by Tessera Israel on account of the Purchase Price before the purchase of the RT Shares is completed will be refundable on the same terms (together with the Option Consideration, the “Refund Amount”). If X SE does not refund the Refund Amount in full when due, Tessera Israel may elect to receive, in full or partial satisfaction of the unpaid portion, ordinary shares of RT held by X SE representing a percentage of the issued and outstanding share capital of RT on a fully diluted basis equal to the greater of (i) 10% and (ii) 15% multiplied by a fraction, the numerator of which is the unpaid portion and the denominator of which is $1,000,000, up to a maximum of 15%. These shares are to be transferred under a standard share purchase agreement to be signed within ten days after Tessera Israel’s notice. Any unpaid portion not satisfied by the transfer of RT shares will remain a debt of X SE, and until the Refund Amount is refunded or satisfied, X SE may not transfer or encumber the RT Shares. The purchase price for the exercise of the Option (the “Purchase Price”) is equal to 51% of the equity value of RT, which is defined as the lower of (i) $13,000,000 and (ii) the sum of two times RT’s average EBITDA plus 10% of RT’s average revenue for fiscal years 2026, 2027 and 2028, as derived from RT’s audited financial statements. Upon exercise of the Option (if any), Tessera Israel is required to pay X SE $2,000,000 on account of the Purchase Price, which includes the Option Consideration, with the remaining $1,000,000 payable at the closing. The balance of the Purchase Price, if any, is to be paid in installments within 30 days after delivery of RT’s audited financial statements for each of fiscal years 2026, 2027 and 2028, calculated each year on the basis of the results available at that time, provided that X SE is required to refund any amount paid in excess of the final Purchase Price. At Tessera Israel’s election, the Purchase Price may be paid in cash, in shares of the Company’s common stock valued at the volume-weighted average price for the 10 trading days before issuance, or in a combination thereof. Any dispute regarding the calculation of the Purchase Price will be resolved by an independent accounting firm agreed by the parties. Any issuance of shares of the Company’s common stock is subject to the approval of the NYSE American, any stockholder approval required under its rules, and an available exemption from registration under the Securities Act of 1933, as amended. Other Terms X SE has agreed to cause RT to enter into a non-exclusive, perpetual license of RT’s technology with Tessera Israel within 60 days after the date of the Option Agreement, whether or not the Option is exercised, and the license will survive any termination of the Option Agreement. If X SE does not refund the Refund Amount in full when due, the license will be royalty-free and irrevocable. Additionally, until the Option expires or the purchase of the RT Shares is completed or terminated, X SE may not, and must cause RT not to, solicit, negotiate or enter into any alternative transaction involving the RT Shares, the equity, assets or business of RT, or an exclusive license of RT’s technology, and X SE may not transfer or encumber the RT Shares. The foregoing description of the Option Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Option Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.